Alnylam Pharmace. buy Sanford C. Bernstein
Start price
07.01.25
/
50%
€228.10
Target price
07.01.26
€298.93
Performance (%)
56.86%
End price
08.01.26
€357.80
Summary
This prediction ended on 08.01.26 with a price of €357.80. With a performance of 56.86% the BUY prediction by Sanford_C__Bernstein was a big success. Sanford_C__Bernstein has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -6.848% | -6.848% | 27.983% |
| iShares Core DAX® | 2,29 % | 9,96 % | 14,44 % |
| iShares Nasdaq 100 | 4,54 % | 8,79 % | 40,87 % |
| iShares Nikkei 225® | 2,81 % | 14,08 % | 47,19 % |
| iShares S&P 500 | 3,10 % | 6,85 % | 31,17 % |
Comments by Sanford_C__Bernstein for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target lowered by analysts at Sanford C. Bernstein from $314.00 to $310.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von Sanford_C__Bernstein gewählte maximale Laufzeit wurde überschritten